Sertraline is Safe During Breastfeeding
Sertraline is one of the preferred antidepressants for breastfeeding mothers and can be safely used while nursing. The medication transfers into breast milk in very low concentrations, and infant exposure remains minimal with negligible clinical effects 1, 2.
Evidence Supporting Safety
The evidence consistently demonstrates that sertraline is among the safest SSRIs during lactation:
Paroxetine and sertraline are the most commonly prescribed antidepressants during breastfeeding 1, with both showing superior safety profiles compared to other SSRIs 3.
Sertraline and paroxetine are minimally excreted in human milk, providing infants less than 10% of the weight-adjusted maternal dose 2. This low transfer rate means the infant receives only a fraction of what would be considered a therapeutic dose.
A 2024 population pharmacokinetic study found that median daily infant dosage was only 6.9 μg/kg after a 50 mg maternal daily dose, representing just 0.95% of the weight-adjusted maternal dose 4. This extremely low exposure provides strong reassurance.
Biological Evidence of Minimal Impact
The most compelling evidence comes from direct measurement of drug effects in infants:
Platelet serotonin transporter studies showed that while mothers experienced 70-96% blockade of serotonin transport, nursing infants showed little or no change in platelet serotonin levels 5. This indicates that despite maternal treatment, the drug concentration reaching infants through breast milk is insufficient to cause meaningful pharmacological effects.
Drug and metabolite concentrations in infants were at or below the lower limit of quantitation in most cases 5.
Practical Prescribing Approach
When prescribing sertraline to breastfeeding mothers:
Continue existing sertraline treatment - Women already taking sertraline should be advised to continue the medication and breastfeed 6.
Start with low doses if initiating treatment - Begin at 25-50 mg daily and titrate slowly upward 6.
Use the lowest effective dose - Target the minimum dose that controls symptoms 6.
Monitor the infant for:
- Irritability or excessive crying
- Poor feeding or decreased appetite
- Sleep disturbances
- Unusual drowsiness
These effects are rare but warrant attention, especially in premature or low birth weight infants 6.
Important Caveats
While sertraline is safe, clinicians should be aware:
CYP2C19 poor metabolizers (the mother, not infant) have 42% reduced sertraline clearance, which could theoretically increase milk concentrations, though clinical significance remains unclear 4.
Breast milk fat content influences transfer - Higher fat content increases the milk-to-plasma ratio by approximately 95%, though absolute infant exposure remains low 4.
The FDA label notes that sertraline is excreted in human milk and recommends caution, but this conservative language predates the robust safety data now available 7.
Timing Considerations (Optional Optimization)
If feasible, mothers can minimize infant exposure by avoiding breastfeeding when milk concentrations peak (typically 7-8 hours post-dose), though this is not necessary given the already minimal exposure 6.
Switching Medications
Do not switch from effective treatment with another antidepressant to sertraline solely for breastfeeding purposes unless there are other compelling clinical reasons 6. The risks of destabilizing maternal mental health outweigh theoretical benefits of switching between safe medications.
Maternal Mental Health Priority
The guideline evidence emphasizes that untreated maternal depression poses significant risks to both mother and infant 2. Withdrawal of effective SSRI treatment can have harmful effects on the mother-infant dyad 2. Therefore, continuing sertraline treatment while breastfeeding represents the optimal balance of risks and benefits in most cases.